Bicycle Therapeutics (NASDAQ:BCYC) Share Price Breaks Above 50 Day Moving Average – Should You Sell?

Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) passed above its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $3.75 and traded as high as $3.84. Bicycle Therapeutics shares last traded at $3.77, with a volume of 590,237 shares traded.

Wall Street Analyst Weigh In

Several research firms recently weighed in on BCYC. Needham & Company LLC cut their target price on shares of Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bicycle Therapeutics in a research note on Friday, October 2nd. Wall Street Zen upgraded shares of Bicycle Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 31st. Jefferies Financial Group reissued a “buy” rating and set a $10.00 price objective on shares of Bicycle Therapeutics in a report on Thursday, October 29th. Finally, Zacks Research downgraded shares of Bicycle Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 14th. Five analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $13.57.

Bicycle Therapeutics Trading Up 4.4%

The firm has a market capitalization of $263.86 million, a P/E ratio of -1.86 and a beta of 1.59. The firm has a 50 day moving average price of $3.75 and a 200-day moving average price of $4.49.

Bicycle Therapeutics (NASDAQ:BCYC) last released its earnings results on Thursday, October 29th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.25. The firm had revenue of $34.06 million for the quarter, compared to the consensus estimate of $12.22 million. Bicycle Therapeutics had a negative return on equity of 26.02% and a negative net margin of 169.75%. Research analysts anticipate that Bicycle Therapeutics PLC Sponsored ADR will post -2.11 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of BCYC. Renaissance Technologies LLC lifted its holdings in shares of Bicycle Therapeutics by 72.8% in the 1st quarter. Renaissance Technologies LLC now owns 979,300 shares of the company’s stock worth $4,544,000 after acquiring an additional 412,700 shares during the last quarter. Principal Financial Group Inc. boosted its stake in shares of Bicycle Therapeutics by 2.3% during the 1st quarter. Principal Financial Group Inc. now owns 1,174,625 shares of the company’s stock worth $5,450,000 after purchasing an additional 26,353 shares during the period. Eversept Partners LP grew its holdings in Bicycle Therapeutics by 6.6% during the 1st quarter. Eversept Partners LP now owns 190,715 shares of the company’s stock valued at $885,000 after purchasing an additional 11,800 shares during the last quarter. Rangeley Capital LLC grew its holdings in Bicycle Therapeutics by 76.0% during the 1st quarter. Rangeley Capital LLC now owns 232,260 shares of the company’s stock valued at $1,078,000 after purchasing an additional 100,260 shares during the last quarter. Finally, Vontobel Holding Ltd. grew its holdings in Bicycle Therapeutics by 15.0% during the 3rd quarter. Vontobel Holding Ltd. now owns 23,000 shares of the company’s stock valued at $85,000 after purchasing an additional 3,000 shares during the last quarter. 86.15% of the stock is owned by hedge funds and other institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a biopharmaceutical company that develops medicines using its proprietary Bicycle molecule technology. Bicycle molecules are small, constrained peptides designed to bind selectively to biological targets while offering characteristics that may support tissue penetration, rapid clearance, and chemical synthesis. The company is primarily focused on creating therapies for cancer and other serious diseases.

Bicycle Therapeutics’ research programs include targeted therapeutics intended to deliver cytotoxic payloads to tumor cells, as well as immune-modulating treatments designed to activate or direct the immune system within the tumor microenvironment.